Literature DB >> 1895401

Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression.

S Joshi1, A Van Brunschot, S Asad, I van der Elst, S E Read, A Bernstein.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4+ lymphocytes and macrophages and causes AIDS in humans. Retroviral vectors allowing neomycin phosphotransferase (npt) gene expression were engineered to express 5' sequences of HIV-1 RNA in the antisense or sense orientation and used to transform the human CD4+ lymphocyte-derived MT4 cell line. Cells expressing antisense or sense RNA to the HIV-1 tat mRNA leader sequence, as part of the 3' untranslated region of the npt mRNA, remained sensitive to HIV-1 infection. In contrast, resistance to HIV-1 infection was observed in cells expressing antisense RNA to the HIV-1 primer-binding site or to the region 5' to the primer-binding site as part of the 3' region of the npt mRNA. Cells expressing the tat mRNA leader sequence in the sense orientation as a precise replacement of the 5' untranslated region of npt mRNA were also resistant to HIV-1. These results indicate that sense and antisense approaches can be used to interfere with HIV-1 multiplication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895401      PMCID: PMC249050     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Molecular biology of HIV: new insights into the virus life-cycle.

Authors:  A J Cann; J Karn
Journal:  AIDS       Date:  1989       Impact factor: 4.177

2.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.

Authors:  M A Muesing; D H Smith; D J Capon
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

3.  Injected anti-sense RNAs specifically block messenger RNA translation in vivo.

Authors:  D A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information.

Authors:  M Zuker; P Stiegler
Journal:  Nucleic Acids Res       Date:  1981-01-10       Impact factor: 16.971

6.  A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA).

Authors:  T Mizuno; M Y Chou; M Inouye
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

7.  Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis.

Authors:  J G Izant; H Weintraub
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

8.  HIV-1 TAT "activates" presynthesized RNA in the nucleus.

Authors:  M Braddock; A Chambers; W Wilson; M P Esnouf; S E Adams; A J Kingsman; S M Kingsman
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

9.  A system for shotgun DNA sequencing.

Authors:  J Messing; R Crea; P H Seeburg
Journal:  Nucleic Acids Res       Date:  1981-01-24       Impact factor: 16.971

10.  Retrovirus transduction: generation of infectious retroviruses expressing dominant and selectable genes is associated with in vivo recombination and deletion events.

Authors:  A L Joyner; A Bernstein
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

View more
  23 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Can hammerhead ribozymes be efficient tools to inactivate gene function?

Authors:  E Bertrand; R Pictet; T Grange
Journal:  Nucleic Acids Res       Date:  1994-02-11       Impact factor: 16.971

Review 3.  Antisense and ribozyme constructs in transgenic animals.

Authors:  D L Sokol; J D Murray
Journal:  Transgenic Res       Date:  1996-11       Impact factor: 2.788

Review 4.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.

Authors:  Y F Melekhovets; S Joshi
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

6.  Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein.

Authors:  T Hamouda; R McPhee; S C Hsia; G S Read; T C Holland; S R King
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat.

Authors:  L Buonocore; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.